Close

Sixth Annual BIO Patient and Health Advocacy Summit Concludes Today

Oct 3 2017
The 2017 Patient and Health Advocacy Summit wrapped up today, having offered the nearly 240 patient groups, companies and organizations new ways to connect, strategize, learn and partner.  For the past six years, the BIO Patient and Health Advocacy Summit has brought together a diverse group of organizations including patient advocacy, health care providers, academia, government, think tanks, professional societies and the biotechnology industry to focus on bringing the patients’ voice to the drug development process. 

BIO to Offer Complimentary Access to One-on-One Partnering™ During J.P. Morgan Healthcare Conference (“JPM Week”)

Sep 28 2017
BIO will offer complimentary access to its proprietary BIO One-on-One Partnering™ during "JPM" week January 7-11, 2018  

BIO Statement on California’s Drug Price Reporting & Transparency Bill

Sep 13 2017
California Senate Bill 17 is bad for patient and does not deliver on its purported promises

FDA Commissioner, Dr. Scott Gottlieb, to Address BIO Patient and Health Advocacy Summit

Sep 5 2017
The head of the United States Food and Drug Administration, Dr. Scott Gottlieb, will be the keynote speaker at the BIO Patient and Health Advocacy Summit, October 2-3 at the Mayflower Hotel in Washington, DC. The annual event brings together attendees representing patient advocacy groups, health care providers, academia, government, think tanks, professional societies and the biotechnology industry and provides a forum for lively discussions on timely health policy issues and best practices. 

PhRMA and BIO Initiate Litigation to Challenge Unconstitutional Provisions of Nevada’s SB 539

Sep 1 2017
Washington, DC (September 1, 2017) – The Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) today initiated litigation in the United States District Court for the District of Nevada challenging provisions of SB 539, a Nevada law that would violate patent rights and negate trade secret protection for designated diabetes medicines in a way that would harm patients and chill future biomedical innovation.

BIO Asks EPA To Use a Forward-Looking Methodology in Setting Renewable Fuel Standards

Aug 31 2017
BIO today submitted comments on EPA's proposed rule on the Renewable Fuel Standard Program: Standards for 2018 and Biomass-Based Diesel Volume for 2019.

BIO Statement on Nomination of Andrei Iancu to Lead U.S. Patent and Trademark Office

Aug 29 2017

Washington, D.C. (August 29, 2017) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement on the nomination of Andrei Iancu to lead the...

BIO Applauds Signing of Food and Drug Administration Reauthorization Act (FDARA)

Aug 18 2017
Enactment of FDA User Fee package important victory for patients, medical innovation

Fireside Chat Speakers, Programming Announced for 2017 BIO Investor Forum

Aug 15 2017
BIO announces programming for the upcoming BIO Investor Conference Oct. 17-18 in San Francisco including Kristina Burow, Managing Director of ARCH Venture Partners and Dr. Richard Scheller, Chief Science Officer & Head of Therapeutics for 23andMe. The annual conference explores global investment trends and opportunities in life sciences. Early and mid-stage private as well as emerging public companies poised for growth in 2018 are the focus of the event.  

BIO: Senate Passage of FDA User Fee Package Important Victory for Patients, Medical Innovation

Aug 3 2017
Washington, DC (August 3, 2017) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement regarding passage of the Food and Drug Administration Reauthorization Act (FDARA) by the U.S. Senate today: